| NCT00046345 | Bristol-Myers Squibb | HIV Infections | 2002-05 | |
| NCT00518297 | Bristol-Myers Squibb|Merck Sharp & Dohme LLC | HIV Infections | 2007-08 | PHASE1 |
| NCT00389207 | Boehringer Ingelheim | HIV Infections | 2006-10 | PHASE3 |
| NCT00242216 | The University of Texas Health Science Center, Houston | HIV Infections | 2004-05 | PHASE4 |
| NCT00420355 | University of Oklahoma|Abbott | HIV Infection | 2007-04 | PHASE4 |
| NCT00004584 | Bristol-Myers Squibb | HIV Infections | 1999-12 | PHASE2 |
| NCT01332227 | Bristol-Myers Squibb | HIV, Combination Therapy | 2011-10 | PHASE4 |
| NCT00067782 | Bristol-Myers Squibb | HIV Infections | 2002-12 | PHASE3 |
| NCT00768989 | Bristol-Myers Squibb|Merck Sharp & Dohme LLC | HIV | 2008-11 | PHASE2 |
| NCT01099579 | Bristol-Myers Squibb | HIV Infections | 2010-10-13 | PHASE3 |
| NCT03019783 | Brigham and Women´s Hospital | HIV | 2011-12 | PHASE2|PHASE3 |
| NCT00874523 | Kirby Institute | HIV Infection | 2009-07 | PHASE3 |
| NCT00312754 | Bristol-Myers Squibb | HIV Infections | 2005-06 | PHASE4 |
| NCT00833482 | Bristol-Myers Squibb | Human Immunodeficiency Virus Type 1 (HIV-1)|HIV Infections | 2009-09 | PHASE1 |
| NCT01592305 | Hoffmann-La Roche | Healthy Volunteer | 2012-05 | PHASE1 |
| NCT00393328 | Bristol-Myers Squibb | HIV Infections | 2006-11 | PHASE1 |
| NCT02566707 | Radboud University Medical Center | HIV-1 Infection | 2015-08 | PHASE2 |
| NCT00814879 | Yale University|Bristol-Myers Squibb|Merck Sharp & Dohme LLC | Acquired Immune Deficiency Syndrome|AIDS|Human Immunodeficiency Virus|HIV Infections | 2009-05 | NA |
| NCT02386098 | ViiV Healthcare|GlaxoSmithKline | HIV Infections | 2015-07-08 | PHASE2 |
| NCT01351740 | University of British Columbia | HIV Infection | 2011-07 | PHASE4 |
| NCT00411957 | The HIV Netherlands Australia Thailand Research Collaboration|Bristol-Myers Squibb | HIV Infections | 2007-01 | PHASE1|PHASE2 |
| NCT01602822 | Kenneth H. Mayer, MD|Bristol-Myers Squibb|Gilead Sciences|Abbott | HIV | 2012-02 | PHASE4 |
| NCT02565888 | Radboud University Medical Center | Hepatitis C|HIV | 2015-11 | PHASE1 |
| NCT01759875 | University of California, San Francisco | Healthy | 2013-01 | PHASE1 |
| NCT02253836 | Boehringer Ingelheim | Healthy | 2005-01 | PHASE1 |
| NCT00426296 | Clinical Alliance for Research & Education - Infectious Diseases, LLC.|GlaxoSmithKline | HIV Infections|Lipodystrophy | 2006-08 | PHASE4 |
| NCT00757783 | Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | HIV | 2008-10 | PHASE4 |
| NCT00307502 | Germans Trias i Pujol Hospital|Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | HIV Infections | 2005-01 | PHASE1 |
| NCT00916448 | Radboud University Medical Center | Endotoxemia|Inflammation|Multi Organ Dysfunction Syndrome|Sepsis | 2009-05 | NA |
| NCT04468087 | Hospital do Coracao | COVID-19 | 2021-02-15 | PHASE2|PHASE3 |
| NCT04022967 | ANRS, Emerging Infectious Diseases|Mylan Laboratories | HIV-1-infection | 2020-09-21 | PHASE3 |
| NCT00118898 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-09 | PHASE3 |
| NCT00074581 | National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network | HIV Infections | 2005-02 | PHASE3 |
| NCT00940771 | Phoenix Children´s Hospital|Bristol-Myers Squibb | Pediatric HIV|HIV Infections | 2009-08-26 | PHASE4 |
| NCT00084019 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2004-07 | NA |
| NCT00811954 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Gilead Sciences|Merck Sharp & Dohme LLC|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA | HIV Infection | 2009-05 | PHASE3 |
| NCT02257008 | Boehringer Ingelheim | Healthy | 2003-03 | PHASE1 |
| NCT00357721 | Bristol-Myers Squibb | HIV Infections|Protease Inhibitor | 2006-06 | PHASE1 |
| NCT00007202 | National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV Infections | | PHASE2 |
| NCT00552240 | Boehringer Ingelheim | HIV Infections | 2007-09 | PHASE4 |
| NCT00357188 | Bristol-Myers Squibb | HIV Infections|Protease Inhibitor | 2006-07 | PHASE1 |
| NCT01394133 | University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infected | 2011-07 | |
| NCT00357240 | Bristol-Myers Squibb | HIV Infections | 2006-06 | PHASE1 |
| NCT01902186 | Giovanni Di Perri|University of Turin, Italy|University of Milan | HIV Infection|Osteopenia | 2014-09 | PHASE4 |
| NCT01255371 | ANRS, Emerging Infectious Diseases|European and Developing Countries Clinical Trials Partnership (EDCTP)|Ludwig-Maximilians - University of Munich|Institute of Tropical Medicine, Belgium|Institut de Recherche pour le Developpement|Swiss National Science Foundation|University of Limpopo|NIMR-Mbeya Medical Research Program (MMRP)+ Mbeya Referral Hospital, Tanzania | HIV | 2012-03 | PHASE3 |
| NCT02652793 | Judit Pich|Fundacion Clinic per a la Recerca Biomédica | Human Immunodeficiency Virus | 2015-11 | NA |
| NCT01421355 | Brigham and Women´s Hospital|National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 2012-05 | PHASE1 |
| NCT00528060 | French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences | HIV Infections | 2008-01 | PHASE2 |
| NCT02116660 | Merck Sharp & Dohme LLC | HIV Infections | 2014-09-03 | PHASE2 |
| NCT00035932 | Bristol-Myers Squibb | HIV Infections | 2001-11 | PHASE3 |
| NCT00869960 | University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) | Healthy | 2009-03 | PHASE4 |
| NCT00544128 | International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan | HIV Infections | 2007-10 | PHASE4 |
| NCT00002240 | Bristol-Myers Squibb | HIV Infections | 1999-03 | PHASE2 |
| NCT00028067 | Bristol-Myers Squibb | HIV Infections | 2001-08 | PHASE3 |
| NCT00977756 | International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2002-08 | |
| NCT01003990 | Bristol-Myers Squibb | HIV | 2002-10 | PHASE3 |
| NCT03923231 | University of Liverpool|Makerere University|Joint Clinical Research Centre- Kampala|Desmond Tutu HIV Foundation|University of Cape Town|European and Developing Countries Clinical Trials Partnership (EDCTP) | HIV+AIDS|Tuberculosis | 2019-09-02 | |
| NCT00883935 | GlaxoSmithKline|Shionogi | Healthy Volunteer | 2009-04 | PHASE1 |
| NCT01368783 | Asan Medical Center|Bristol-Myers Squibb | Atazanavir | 2011-06 | PHASE1 |
| NCT00082394 | GlaxoSmithKline | Infection, Human Immunodeficiency Virus I|HIV Infection | 2004-04-26 | PHASE4 |
| NCT00751153 | Peter J. Ruane, M.D., Inc. | HIV Infections | 2008-03 | PHASE4 |
| NCT00362726 | Bristol-Myers Squibb | HIV Infections | 2006-09 | PHASE1 |
| NCT00260078 | National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | 2006-02 | PHASE1|PHASE2 |
| NCT00720590 | Indiana University|National Heart, Lung, and Blood Institute (NHLBI) | Endothelial Dysfunction | 2003-11 | NA |
| NCT00224445 | Gilead Sciences | HIV Infections | 2005-09 | PHASE4 |
| NCT01829802 | Pedro Cahn|Merck Sharp & Dohme LLC | Chronic Infection With HIV | 2014-05 | PHASE4 |
| NCT03194165 | Assistance Publique - H?pitaux de Paris|URC-CIC Paris Descartes Necker Cochin | Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed | 2017-06-16 | |
| NCT01307488 | Fundacion SEIMC-GESIDA|Bristol-Myers Squibb | HIV Infection | 2011-09 | PHASE4 |
| NCT01928407 | Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba | HIV-1 Infection|Immunosuppression-related Infectious Disease | 2011-02-23 | PHASE4 |
| NCT00122577 | French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences | HIV Infections | 2002-03 | PHASE2 |
| NCT00447070 | Foundation for Cardiovascular Research, Zurich|Bristol-Myers Squibb | HIV Infections|Dyslipidemia | 2004-08 | PHASE4 |
| NCT00326716 | Bristol-Myers Squibb | HIV Infection | 2006-06 | PHASE1 |
| NCT01335698 | Bristol-Myers Squibb | HIV | 2011-05-27 | PHASE3 |
| NCT00885482 | Catholic University of the Sacred Heart | HIV Infections | 2009-05 | PHASE4 |
| NCT02542852 | Castagna Antonella|Bristol-Myers Squibb|ViiV Healthcare | HIV-1 Infection | 2015-09 | PHASE2 |
| NCT00225017 | Northwestern University|Bristol-Myers Squibb | HIV Infection|Hyperlipidemia | 2005-06 | PHASE3 |
| NCT00440947 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus I|HIV Infection | 2007-03 | PHASE3 |
| NCT02034838 | Ottawa Hospital Research Institute|Bristol-Myers Squibb | HIV Infection | 2014-01 | PHASE1 |
| NCT01591850 | Hoffmann-La Roche | Healthy Volunteer | 2011-09 | PHASE1 |
| NCT00943540 | Radboud University Medical Center | HIV Infection|HIV Infections | 2009-07 | PHASE2 |
| NCT00280969 | International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan | HIV Infection | 2005-09 | PHASE3 |
| NCT00162149 | Bristol-Myers Squibb | HIV Infections | 2005-10 | PHASE1 |
| NCT00878306 | University of California, San Francisco|National Institute on Drug Abuse (NIDA) | HIV Infections|Drug Abuse | 2008-11 | PHASE1 |
| NCT00207142 | Bristol-Myers Squibb | HIV Infections | 2005-11 | PHASE4 |
| NCT04263350 | Bristol-Myers Squibb | Healthy Participants | 2020-02-26 | PHASE1 |
| NCT00160329 | Stanford University|Bristol-Myers Squibb | Hyperlipidemia|HIV Infections | 2004-01 | PHASE3 |
| NCT01803074 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus|HIV Infections | 2013-04-04 | PHASE2 |
| NCT00762892 | The University of Texas Health Science Center, Houston|Merck Sharp & Dohme LLC | HIV Infections | 2009-01 | PHASE4 |
| NCT01384734 | ViiV Healthcare | Infection, Human Immunodeficiency Virus | 2011-07-26 | PHASE2 |
| NCT01388543 | University of Colorado, Denver|National Institute of Allergy and Infectious Diseases (NIAID) | HIV | 2006-09 | PHASE4 |
| NCT00084136 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 2005-05 | PHASE4 |
| NCT01620944 | Bristol-Myers Squibb | HIV | 2012-07-31 | PHASE3 |
| NCT00096850 | National Institute of Allergy and Infectious Diseases (NIAID)|Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections | HIV Infections|Tuberculosis | | NA |
| NCT01274780 | Juan A. Arnaiz | HIV-1 | 2011-05 | PHASE4 |
| NCT01656109 | The HIV Netherlands Australia Thailand Research Collaboration|amfAR, The Foundation for AIDS Research|National Health Security Office, Thailand|The Thai Government Pharmaceutical Organization (GPO) | HIV | 2011-07 | PHASE2 |
| NCT04184869 | Acrotech Biopharma Inc.|Axis Clinicals Limited | Solid Tumor|Hematological Malignancies | 2019-08-05 | PHASE1 |
| NCT01232127 | Bristol-Myers Squibb | HIV | 2011-02 | PHASE4 |
| NCT05236738 | Bristol-Myers Squibb | Healthy Participants | 2022-05-13 | PHASE1 |
| NCT01445223 | G?teborg University | HIV | 2004-04 | PHASE4 |
| NCT02473328 | Centre de Recherches et d´Etude sur la Pathologie Tropicale et le Sida|INSERM UMR S 1136 | HIV-1 Infection | 2015-06 | PHASE2 |
| NCT00696722 | Radboud University Medical Center|Dutch Diabetes Research Foundation | Type 2 Diabetes Mellitus Related Endothelial Dysfunction | 2008-06 | PHASE2 |
| NCT02102048 | University of Roma La Sapienza | HIV | 2009-01 | NA |
| NCT00337467 | Bristol-Myers Squibb | Human Immunodeficiency Virus (HIV) Infections | 2006-06 | PHASE3 |
| NCT00013520 | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | PHASE3 |
| NCT00355719 | Germans Trias i Pujol Hospital|Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia|Hospital San Jaime de Calella | HIV Infections | 2007-01 | PHASE4 |
| NCT01691794 | Bristol-Myers Squibb | HIV, Pediatric | 2012-11-30 | PHASE4 |
| NCT00135356 | Bristol-Myers Squibb | HIV-Associated Lipodystrophy Syndrome | 2005-07 | PHASE4 |
| NCT00896051 | Janssen R&D Ireland | HIV Infections|Acquired Immunodeficiency Syndrome | 2009-08 | PHASE2 |
| NCT01818856 | Hospitales Universitarios Virgen del Rocío|Bristol-Myers Squibb | Hepatitis C, Chronic|HIV Infection | 2012-12 | PHASE1 |
| NCT01599364 | Catholic University of the Sacred Heart | Human Immunodeficiency Virus | 2014-04 | PHASE4 |
| NCT01837719 | Bristol-Myers Squibb | Human Immunodeficiency Virus Type 1 (HIV-1) | 2013-04 | PHASE1 |
| NCT01180075 | University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID) | Human Immunodeficiency Virus | 2010-05 | |
| NCT01605084 | Bristol-Myers Squibb | HIV | 2012-06-30 | PHASE3 |
| NCT00013897 | Bristol-Myers Squibb | HIV Infections | 2001-02 | PHASE3 |
| NCT00646776 | Bristol-Myers Squibb | Antivirals+HIV | 2008-04 | PHASE1 |
| NCT01404572 | Bristol-Myers Squibb | HIV | 2011-08 | PHASE1 |
| NCT01910402 | ViiV Healthcare|GlaxoSmithKline | Infection, Human Immunodeficiency Virus|HIV Infections | 2013-08-22 | PHASE3 |
| NCT00851799 | Advancing Clinical Therapeutics Globally for HIV+AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection | 2009-06 | |